Un-locking 🔐 Data to Transform Biology (part III)
Un-locking 🔐 Data to Transform Biology (part III)
Trends on TechBio: New Atlantis, IPA (BioStrand, Talem), Aging Intervention Foundation, Synthace, Blume VC, Elucidate Bio and Genesis Therapeutics
Un-locking 🔐 Data to Transform Biology (part I)
Trends on TechBio: WhiteLab Genomics, Sinopia, Cure51, Owkin, Parallel Bio, PipeBio, Turbine AI, IridescentBio Bio and Peptone
Un-locking 🔐 Data to Transform Biology (part II)
Trends on TechBio: Pace Ventures, Giant Ventures, Trisonic Discovery, Thoughtworks, Big_Bets, Cradle Bio, Mercia and Octant Bio
Un-locking 🔐 Data to Transform Biology (part III)
Trends on TechBio: New Atlantis, IPA (BioStrand, Talem), Aging Intervention Foundation, Synthace, Blume VC, Elucidate Bio, Amplify Partners and Genesis Therapeutics
“Their philosophy was that you should not always trust your senses and sense experience in order to understand the world, but should rely ultimately on logic and mathematics.”
Jim Al-Khalili, Paradox: The Nine Greatest Enigmas in Physics
New Atlantis Labs, marine metagenomics
NewAtlantis (US)—dedicated to marine biodiversity and marine metagenomics for saving our oceans and preserving marine biodiversity—is about to quantify marine biodiversity 🐠 with open meta omics to power sustainable and scalable ocean regeneration. At New Atlantis they believe that the phylogenetic diversity of the largely un-sequenced marine microbes and planktonic communities could provide a lot of novel potential secondary metabolites that might be of commercial interest. And with a partnership with Bacalhau—a platform for faster, cost efficient and more secure distributed computation, enabling users to run arbitrary Docker containers and WebAssembly images as tasks—they want to study the genome of the marine micro-organisms sampled directly from the ocean environment, using new high-throughput DNA sequencing technology and bioinformatics tools.
But there is more. Gordon Gould—the co-founder and co-CEO of New Atlantis—and his team don’t just want to protect the Marine Protected Areas (MPAs), the national parks of the oceans around the globe. They want also to empower the communities around the MPAs—that most of the times lack the resources to adequately protect life in their waters due to reliance on precarious government funding and traditional philanthropy—by providing MPAs with a viable business model that generates revenues based on MPA conservation efforts and outcomes achieved in their waters, by creating an open marine metagenomics biodiversity analytics platform from which ecosystem health can be evaluated in order to issue blue carbon and biodiversity credits as a revenue source for MPAs (biodiversity credits and parametric insurance products). Courtney Nichols Gould, Gordon’s wife, is the co-founder and co-CEO of New Atlantis Labs.
But what do you get when you blend the blue economy with biology and data science? You actually get a time travel back to our origins that gives you the possibility to study biological pathways, proteins and genes (of known and unknown metabolites) in different time points throughout evolution, enabling in the end the pharma sector and the tech sector to build more efficient AI models for drug discovery.
🌶 This month NewAtlantis Labs met with the The Erdős Institute, where NewAtlantis was honored to get the chance to mentor this incredible group of data scientists working to create open source ML systems to model and predict ecosystem health (modeling the relationship between chlorophyll and fishery measures).
If you're an NGO, government, a community leader, a lab, or a philanthropist interested in partnering with them, just let them know!
ImmunoPrecise Antibodies Ltd (IPA)
IPA (1983, Canada) is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry’s most trusted independent market research sources with the highest competitive score for its antibody service portfolio.
The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. They provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services (Talem)—with advanced omics and complex intelligence technology (LENSᵃⁱ) that provide greater efficiency and accuracy than ever before.
LENSai™ Integrated Intelligence Technology powered by HYFTs® (Universal FingerprintsTM)—that seamlessly integrates massive data from diverse data sources to enhance LLMs and accelerate antibody discovery—was developed by BioStrand, founded in Belgium in 2019, and is an independently operating subsidiary of IPA at the intersection of biotech discovery, biotherapeutics and AI.
Talem Therapeutics LLC is also a subsidiary of IPA and is focused on the discovery and development of next-generation, human, monoclonal, therapeutic antibodies.
IPA has also a research collaboration and exclusive option license agreement (as of March 30, 2023) with Xyphos Biosciences, Inc (a wholly owned subsidiary of Astellas Pharma Inc, TYO: 4503) to jointly conduct research activities to identify and optimize proprietary LENSᵃⁱ in silico generated antibodies, targeting an undisclosed target in the tumor microenvironment, as potential therapeutic development candidates. Targeting this molecule has the potential to markedly enhance anti-tumor immunity with other Astellas therapies including chimeric antigen receptor-based (CAR) technologies. Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.
🌶 On September 16, 2024, ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025.
ImmunoPrecise continues to execute its growth strategy, focusing on scaling its AI-driven antibody drug discovery platforms, expanding its global client base, and optimizing operational efficiencies.
IPA's protein manufacturing site experienced a year-over-year decline this quarter, this was primarily due to an exceptionally strong performance in the previous year and rebuilding off-the-shelf inventory of higher-margin products.
BioStrand is driving revenue growth through its LENSai platform, offering fee-for-service solutions while developing commercial products tailored to IPA's extensive client base of over 600 companies.
Recently, BioStrand achieved a significant breakthrough by developing and optimizing antibodies entirely through computer simulations, targeting a protein within the Tumor Microenvironment (TME).
Building on this AI-driven success, BioStrand is now accelerating the rollout of advanced in silico antibody engineering solutions, positioning the company at the forefront of computational drug discovery and potentially opening new revenue streams in this high-growth market segment.
BioStrand is also making progress in developing applications for the AWS Marketplace.
Talem Therapeutics and BioStrand have partnered to enhance Talem's lead therapeutic assets using BioStrand's LENSai software suite, which includes over 80 in silico applications.
Dr. Jennifer Bath is the Chief Executive Officer and President and Frederic Chabot is Head of Corporate Development at IPA.
Aging Intervention Foundation
Aging Intervention Foundation has a mission to increase Healthspan and Lifespan, and to slow and ultimately reverse biological aging and age-related decline for more years of healthy living, utilizing the following modalities:
Gene therapy and AI for drug design and biomarker analysis
Plasma Therapies, therapeutic plasma exchange/removal of pro-aging factors and adding youth enhancing factors
Mitochondrial therapies
Yamanaka/OSK systemic therapy, reset the epigenome toward youth/cellular reprogramming
Personalized Microbiome therapies
NAD and NAD enhancement supplements, AlphaKetoglutarate (AKG), nutritional supplements and Kaufmann protocol, cognitive and life enhancement
Senolytics, Peptides, Exosomes, Engineered Reprogramming Extracellular Vesicles (VSELs) and Protein profile control. For more
The Aging Intervention Foundation is run by Johnny Adams, that he is actively looking right now for exceptional people to create aging solutions, money to make it happen, grants for exceptional researchers, as well as to fund companies for equity and to partner with labs in the US and offshore working on TechBio Longevity. His supporters will get early access to longevity therapies, valuable information and money if they desire.
In his Scientific Advisory Board you can find “great minds” 🧠 like:
Alexander Zhavoronkov, PhD CEO and founder of Insilico Medicine (Insilico Medicine 10 Years of AI Drug Discovery Innovation)
Longevity and TechBio Latest News
🌶 Viome lands $25m to launch new diagnostics division
🌶 Cellino lands $25m ARPA-H funding to ramp production of regenerative stem cells
🌶 OrsoBio lands $67m to treat metabolic disease by restoring energy homeostasis
